MEI Pharma Inc (MEIP): Earnings growth forecast for next year

Corporate company logo of MEI Pharma (MEIP)

MEI Pharma, Inc. (MEIP) develops targeted methods for suppressing tumor metabolism, and the GURU.Markets portal displays the expected earnings per share growth rate, where 0.00 serves as the current parameter value. Diversification of hematological programs at various stages minimizes risks. Meanwhile, long-term catalysts for portfolio development are only beginning to form, while cost optimization is already priced in.

MEI Pharma Inc (MEIP): Expected earnings per share growth for next year from 07/04/2022 to 09/11/2025

MEIP (meipharma.com): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Chart MEI Pharma Corp|MEIP - Average Forecast Price
- stock exchange capitalization data:
Market Capitalization MEI Pharma|MEIP - Business Value
- book capitalization indicators:
Net Assets per Single Share MEI Pharma|MEIP - Company Net Assets|Market Capitalization to Book Value Ratio meipharma.com|MEIP - Company Assets
- debt obligations and liquidity statistics:
Total Debt to Capital MEI Pharma, Inc.|MEIP - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio MEI Pharma|MEIP - Aggregate Debt Obligations|Debt to Book Capitalization Ratio MEI Pharma|MEIP - Long-Term Liabilities|Company Short-Term Debts MEI Pharma|Quick Ratio meipharma.com
- net income and valuation ratios data:
MEIP - Net Profit|Expected Profit MEI Pharma, Inc.|MEIP - Company Value to Net Income|Future Price to Earnings MEI Pharma, Inc.|MEIP - Price/Earnings to Growth Multiple|EV/EBITDA Multiple MEI Pharma|MEIP - Operating profit EBITDA|Net earnings per share for the last 12 months MEI Pharma|MEIP - Earnings per share for the trailing year|Quarterly EPS earnings growth meipharma.com|MEIP - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year MEI Pharma, Inc.
Fundamental company valuation:MEIP, MEI Pharma Corp
Finished products of MEI Pharma Inc

This indicator measures the rate of revision for the stock's future returns, determining the discounting speed of profit prospects under current monetary policy. By analyzing the forward EPS dynamics model for MEI Pharma, Inc. (MEIP), an investor can see how the security of oncology drug substance supplies and logistics diversification translate into the stability of expected earnings, allowing for the avoidance of loss crystallization during a cyclical downturn.

Who MEI Pharma, Inc. competes with

Net earnings per share growth forecast for next year TG Therapeutics Corp|Expected net earnings per share growth next year Arcellx Therapeutics ACLX|Earnings growth forecast for next year IRON|syndax.com - Projected earnings per share growth rate for next year|Net earnings per share growth forecast for next year Kura Oncology KURA|ADCT - Expected earnings per share growth for next year|Foghorn - Earnings growth forecast for next year|Expected net earnings per share growth next year Vor Bio Inc.|NKTX: Earnings growth forecast for next year|COEP - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year ATNM|ESLA: Expected earnings per share trend next year|Net earnings per share growth forecast for next year CASI Pharmaceuticals (CASI)|MRKR: Net earnings per share change forecast for next year|Earnings growth forecast for next year INAB (IN8bio, Inc.)|Expected earnings per share trend next year ERNA|GT Biopharma - Earnings growth forecast for next year|APTO - Earnings growth forecast for next year|Bio-Path (BPTH) - Net earnings per share growth forecast for next year|Vincerx Pharma - Expected earnings per share trend next year